Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells. Issue 3 (1st February 2019)

• Record Type: Journal Article
• Authors: Long, Cheng; Chen, Juan; Zhou, Hua; Jiang, Tao; Fang, Xiang; Hou, Dong; Liu, Ping; Duan, Hong
• Is Part Of: Cell cycle. Volume 18:Issue 3(2019)
• Page Start: 346
• Page End: 358
• Publication Date: 2019-02-01
• Subjects: Diosgenin -- osteosarcoma -- Cdc20 -- cell growth -- apoptosis; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2019.1568748
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Osteosarcoma (OS) is one of the aggressive malignancies for young adults. Cdc20 (cell division cycle 20 homologue) has been reported to exhibit an oncogenic role in OS, suggesting that inhibition of Cdc20 could be a novel strategy for the treatment of OS. Since Cdc20 inhibitors have side effects, it is important to discover the new CDC20 inhibitors with non-toxic nature. In the present study, we determine whether natural agent diosgenin is an inhibitor of Cdc20 in OS cells. We performed MTT, FACS, Wound healing assay, Transwell, Western blotting, transfection assays in our study. We found diosgenin inhibited cell growth and induced apoptosis. Moreover, diosgenin exposure led to inhibition of cell migration and invasion. Notably, diosgenin inhibited the expression of Cdc20 in OS cells. Overexpression of Cdc20 abrogated the inhibition of cell growth and invasion induced by diosgenin. Our data reveal that inhibition of Cdc20 by diosgenin could be helpful for the treatment of patients with OS.